Meral KOYUNCUOĞLU, Gözde GÖRÜCÜ, Uğur SAYGILI, Bilkay İlknur GÖRKEM, Emek ÖZEN, Turhan USLU, Oktay ERTEN

Endometrioid adenokarsinomlarda Heat-shock protein 70, 90 ve tenasin ekspresyonunun myometrial invazyon derinliği ile ilişkisi

Amaç: Endometrial kanserli olgularda HSP70, 90 ve tenasinin immunohistokimyasal ekspresyonunu incelemek ve HSP70, 90 ve tenasin ekspresyonu ile histolojik derece, evre, yaş ve myometrial İnvazyon ile ilişkisini araştırmaktır. Gereç ve Yöntem: Bu çalışmada 78 endometrial kanserli olguda HSP70, 90 ve tenasinin ekspresyonu immuııohistokimyasal yöntemle incelendi ve HSP70, 90 ve tenasin ekspresyonu ile histolojik derece, evre, yaş ve myometrial İnvazyon ile ilişkisi araştırıldı. Bulgular: HSP 70 ekspresyonu olguların %89.7'sinde (70 olgu) görüldü. HSP70 ekspresyonu ile histolojik derece, evre ve yaş arasında ilişki yoktu. Ancak myometrial İnvazyon derinliği ile ilişki saptandı (p

Anahtar Kelimeler:

Seyir, Neoplazm evrelendirilmesi, Tenaskin, Isı-şok proteinleri 90, Isı-şok proteinleri 70, Endometriyum neoplazmları, İmmünohistokimya

The relationship between Heat-shock protein 70, 90 expression and myometrial invasion

Object: Our aim is to investigate to immunohistochemical expression of HSP 70,90 and tenascin in endometrioid adenocarcinoma and to search for the relationship between HSP 70,90 and tenascin expression and histological grade, stage, age and myometrial invasion. Material and method: We analyzed the expression of HSP 70,90 and tenascin by immunohistochemistry in 78 -cases with endometrioid adenocarcinoma and the relationship between HSP 70,90 and tenascin expression and histological grade, stage, age and myometrial invasion. Results: The expression of HSP 70 was observed in 89.7% (70 cases). There was no relationship between HSP70 expression and histological grade, stage and age. But we found positive relationship between HSP 70 expression and myometrial invasion (p<0.05). The expression of HSP90 and tenascin C were observed in 60.5% (48 cases), 34.6% (27 cases) respectively. There was no relationship between HSP90 and tenascin expression and histological grade, stage and myometrial invasion. Conclusion: The expression of HSP 70 in endometrioid adenocarcinoma may be considered as a poor prognostic factor.

Keywords:

Prognosis, Neoplasm Staging, Tenascin, Heat-Shock Proteins 90, Heat-Shock Proteins 70, Endometrial Neoplasms, Immunohistochemistry,

___

1. Kurman RJ, Zaino RJ, Norris HJ. Endometrial Carci¬ noma. In. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag, 1994:439- 486.
2. Longacre TA, Kempson RL, Hendrickson MR. Endo¬ metrial hyperplasia, metaplasia and carcinoma. Obstet¬ rical and Gynaecological pathology (Ed. Fox H.). 4th Ed. Churchill Livingstone, New York, 1995:421-511.
3. Rose PG. Endometrial carcinoma. N. England J Med 1996:335; 640-649.
4. Homesley HD, Zaino R. Endometrial Cancer: Prognos¬tic Factors. Semin in Oncol 1994:21; 71-78.
5. Gehring PA, Van LL, Olatidoye B, et al. Estrogen receptor status determined by immunohistochemistry as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86:2083-2089.
6. Gordon MD, Ireland K. Pathology of hyperplasia and carcinoma. Semin Oncol 1994; 21:64-70.
7. Aziz H, Hussain F, Edelman S, et al. Age and race as prognostic factors in endometrial carcinoma. Am J Clin Oncol 1996; 19:595-600.
8. Daniell HJ. More Advanced-stage tumors among smokers with endometrial cancer. Am J Clin Pathol 1993;100:439-443. 9. Clement PB, Scully RE. Endometrial hyperplasia and carcinoma. In: Tumors and Tumorlike Lesions of the Uterine Corpus and Cervix (Ed. Clement PB, Young RH). 1st Ed. Churchill Livingstone, New York, 1993:181-264.
10. Hakala A, Kacinski BM, Stanley ER, et al. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA125 and the aminoterminal propeptide of type III procollagen. Am J Obstet Gynecol 1995;173:112- 119.
11. Davies JL, Rosenshein NB, Anunes CM, et al. A review of the risk factors for endometrial carcinoma. Obs Gyn Survey 1981; 36:107-116.
12. Ambros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992;69:1424-1431.
13. Zaino RJ, Silverberg SG, Norris HJ, et al. The prognos¬ tic value of nuclear versus architectural grading in en¬ dometrial adenocarcinoma. Int J Gynecol Pathol 1994; 13:29-36.
14. Valsacchi L, Mangili G, Frigerio L, et al. Reliability of preoperative evaluation of prognostic factors in endo¬ metrial carcinoma. Int J Gynecol Obstet 1997; 59:35-39.
15. Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic supressor gene status in endo¬ metrial carcinoma with particular emphasis on p53. Cancer 1994:73;1686-1692.
16. Benevolo M, Mariani L, Vocaturo G, et al. Independent prognostic value of peritoneal immunocytodiagnosis in endometrial carcinoma. Am J Surg Pathol 2000; 24:241- 247.
17. Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohisto¬ chemistry in endometrial carcinoma. Gynecol Oncol 1998; 69:220-225.
18. Pertschuk LP, Masood S, Simone J, et al. Estrogen receptor immunocytochemistry in endometrial carci¬ noma: a prognostic marker for survival. Gynecol Oncol 1996; 63:28-33.
19. Navari JR, Roland PY, Keh P, et al. Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. Clin Cancer Res 2000; 6:4026-4032.
20. Özsaran AA, Türker S, Dikmen Y, et al. p53 staining as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:156-159.
21. Jika K. Sassano H, Ito K, et al. Immunohistochemical and in situ hybridization analysis of p53 in human en¬ dometrial carcinoma of uterus. Anticancer Res 1993; 13:305-310.
22. Lukes AS, Kohler MP, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53 and HER-2/neu as prog¬ nostic farctors in endometrial cancer. Cancer 1994; 73:2380-2385.
23. Wataba K, Saito T, Fukunaka K, et al. Over-expression of heat shock proteins in carcinogenic endometrium. Int J Cancer 2001 15; 91:448-456.
24. Nylandsted J, Rohde M, Brand K, et al. Selective deple¬ tion of heat shock protein 70 (HSP70) activates a tu¬ mor-specific death program that is independent of cases and bypasses Bcl-2. Cell Biology 2000; 97:7871- 7886.
25. Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 1998; 22:549-455.
26. Geisler JP, Geisler HE, Tammela J, et al. A study of heat shock protein 27 in endometrial carcinoma. Gyne- col Oncol 1999; 72:347-350.
27. Ciocca DR, Fvrqua SA, Lock-Lim S, et al. Response of human breast cancer cells to heat shock and chemo- therapeutic drugs. Cancer Res 1992:52; 3648-3654.
28. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialiaed emryonic tis¬ sues and tumors. Annu Rev Cell Biol 1989; 5:71-92.
29. Koukoulis GK, Gould VE, Bhattacharyya A, et al. Tenascin in normal, reactive, hyperplastic and neoplas- tic tissue: Biologic and pathologic implications. Hum Patholl 991; 22:636-643.
30. Koukoulis GK, Howeedy AA, Korhonen M, et al. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicro Cytol Pathol 1993; 25:285-95.
31. Juhasz A, Bardos H, Repassy G, et al. Characterise distribution patterns of tenascin in laryngeal and hyh0 pharyngeal cancers. Laryngoscope 2000;l 10:84-92.
32. Jahkola T, Toivonen T, Virtanen I, et al. Tenascin-f expression in invasion border of early breast cancer: & predictor of local and distant recurrence. Br J Cancer 1998; 78:1507-1513.
33. Ramos DM, Chen B, Regezi J, et al. Tenascin-C matrix assembly in oral squamous carcinoma. Int J Cancer 1998; 75:680-687.
34. Goepel C, Bruchmann J, Schultka R, et al. Tenascin- a marker for the malignant potential of preinvasive breast cancers. Gynecol Oncol 2000; 79:372-378.
35. Xue Y, Li J, Latijnhouwers M, et al. Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol 1998; 81:844-851.
36. Kressner U, Lindmark G, Tomasini-Johansson, et al. Stromal tenascin distribution as a prognostic marker in colorectal cancer. Br J of Cancer 1997; 76:526-530.
37. Nordstrom B, Strang P, Bergstrom R, et al. A compari¬ son of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proli¬ ferating cell nuclear antigen, and flow cytometric S- phase fraction. Cancer 1996; 78:1942-1951.
38. Doi D, Araki T, Asano A. Immunohistochemical local¬ ization of tenascin, estrogen receptor and transforming growth factor-beta 1 in human endometrial carcinoma. Gynecol Obstet Invest 1996; 41:61-66.
39. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 4,92:1564-1572.
40. Mestiri S, Bouaouina N, Ahmed SB, et al. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001 ;91:672-678. ;:
41. Ricaniadis N, Kataki A, Agnantis N, et al. Long-term prognostic significance of HSP-70, c-myc and HLA- DR expression in patients with malignant melanoma. Eur J Surg Oncol 2001;27:88-93.
42. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-00 IL-6 and İL-10 in bladder cancer. Anticancer Res 2000;20:4579-4583.
43. Park KC, Kim DS, Choi HO, et al. Overexpression of HSP70 prevents ultraviolet B-induced apoptosis of a human melanoma cell line. Arch Dermatol Res 2000; 292:482-487.
44 Trieb K, Kohlbeck R, Lang S, et al. Heat shock protein 72 expression in chondrosarcoma correlates with dif¬ferentiation. J Cancer Res Clin Oncol 2000; 126:667-670.
45. Iskaros BF, Koss LG. Tenascin expression in intraepi- thelial neoplasia and invasive carcinoma of the uterine cervix. Arch Pathol Lab Med 2000; 124:1282-1286.
46. Schenk S, Chiquet-Ehrismann R, Battegay EJ. The Fibrinogen Globe of Tenascin-C Promotes Basic Fi- broblast Growth Factor-induced Endothelial Cell Elongation. Cell Biology 1999; 10:2933-2943.
47. Iskaros BF, Hu X, Sparano JA, et al. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J Surg Oncol 1998; 68:107-112.
48. Kim CH, Bak KH, Kim YS, et al. Expression of tenas- cin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 2000;54: 235-240.
49. Rosette JJ, Schalken JA. Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate car¬ cinoma. Br J Urol 1998;81:844-851.
50. Xue Y, Smedts F, Latijnhouwers MA, et al. Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression? Anticancer Res 1998; 18:2679- 2684.
51. Kahn HJ, Fekete E, From L. Tenascin differentiates dermato fibroma from dermatofibro sarcoma protuber- ans: comparison with CD34 and factor Xllla. Hum Pathol 2001; 32:50-56.